Clene Inc.
NASDAQ:CLNNBiotechnology
+$0.08 today
- Market cap
- $52.70M
- Beta
- 0.92
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$2.88
Volume 0.12M
Average 0.50M
CLNN Total Current Assets
All assets expected to be converted to cash or used up within one year.
Clene Inc.NASDAQ: CLNN
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets falls 11.2% from a year ago
Total current assets stood at $13.02M at the end of Q1 FY2026, down 11.2% from a year earlier and up 45.1% from the prior quarter. Over 3 fiscal years it compounded at -32.5% a year.
Context
- Total current assets amounted to 60.1% of total assets at the end of Q1 FY2026, up 2.2 pp from a year earlier.
- Total current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps falling in the next quarterly balance sheet after a -11.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 8.98M USD
- Year-over-year change
- -44.4%
- 4-year CAGR
- -36.3%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.98M | -44.4% |
| FY2024 | 2024-12-31 | 16.16M | -58.4% |
| FY2023 | 2023-12-31 | 38.85M | +33.1% |
| FY2022 | 2022-12-31 | 29.2M | -46.5% |
| FY2021 | 2021-12-31 | 54.58M | — |
Total Current Assets vs competitors
How CLNN compares with its peers on the latest reported figures
- CLNN's Mar 2026 total current assets of $13.02M is the lowest of the 11 companies compared; the peer median is $109.65M.
- Its year-over-year change of -11.2% is the 5th highest of 11, against a peer median of -36.6%.
- Total current assets amounts to 60.1% of total assets for CLNN, versus a peer median of 88.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $218.1M | -36.4% | -17.6% | 86.2% | |
| Mar 2026 | $182.52M | +0.2% | -0.3% | 83.8% | |
| Mar 2026 | $174.93M | -43.8% | -16.7% | 86.3% | |
| Mar 2026 | $160.15M | +248.7% | -11.7% | 71.0% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | $125.55M | -46.0% | -6.1% | 98.7% |
| Mar 2026 | $93.75M | +41.2% | -23.6% | 91.8% | |
| Mar 2026 | $68.15M | -48.2% | -5.3% | 25.3% | |
| Mar 2026 | $58.52M | -36.9% | +21.8% | 99.4% | |
| Mar 2026 | $53.26M | +38.8% | +90.8% | 100.0% | |
| Dec 2025 | $50.93M | -47.5% | -31.1% | 90.8% | |
| Mar 2026 | $13.02M | -11.2% | -32.5% | 60.1% | |
| Peer median (excluding CLNN) | $109.65M | -36.6% | -8.9% | 88.6% | |
Competitors are the stored peer set for CLNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 50.29M | 18.33M | 28.82M | 12.16M | 5.19M |
| Short-term Investments | 0 | 4.98M | 6.18M | 0 | 0 |
| Net Receivables | 1.61M | 2.97M | 1.34M | 391K | 590K |
| Inventory | 41K | 43K | 37K | 68K | 37K |
| Other Current Assets | 2.45M | 2.87M | 2.48M | 137K | 139K |
| Total Current Assets | 54.58M | 29.2M | 38.85M | 16.16M | 8.98M |
| Property, Plant & Equipment (Net) | 8.42M | 15.24M | 13.43M | 11.12M | 9.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 58K | 58K | 0 | 58K | 58K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 58K | 0 | 0 |
| Total Non-current Assets | 8.48M | 15.3M | 13.49M | 11.18M | 9.15M |
| Total Assets | 63.06M | 44.49M | 52.34M | 27.34M | 18.13M |
| Account Payables | 1.92M | 3.01M | 1.5M | 1.24M | 892K |
| Short-term Debt | 0 | 6.42M | 19.5M | 359K | 4.07M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 520K | 520K | 0 | 2.67M | 1.51M |
| Other Current Liabilities | 2.05M | 1.49M | 2.12M | 4.08M | 3.14M |
| Total Current Liabilities | 6.03M | 13.86M | 25.33M | 10.29M | 10.78M |
| Long-term Debt | 19.08M | 19.25M | 7.15M | 15.43M | 13.54M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 20.89M | 2.56M | 1.57M | 6.35M | 8.16M |
| Total Non-current Liabilities | 44.44M | 27.4M | 13.62M | 25.9M | 24.95M |
| Total Liabilities | 50.47M | 41.26M | 38.95M | 36.19M | 35.72M |
| Common Stock | 6K | 7K | 13K | 1K | 1K |
| Retained Earnings | (163.3M) | (193.22M) | (242.72M) | (282.12M) | (308.3M) |
| Accumulated OCI | 233K | 203K | 199K | 71K | 172K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 12.6M | 3.24M | 13.39M | (8.86M) | (17.59M) |
| Total Debt | 24.04M | 31.82M | 32.16M | 20.84M | 21.67M |
| Net Debt | (26.25M) | 13.49M | 3.34M | 8.69M | 16.48M |
Clene Inc.
NASDAQ:CLNN
Intrinsic Alpha fair value
Locked
Current Price
$3.66
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.